Trial · NCT03447990
Adverse events900
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
201 to 220 of 900
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Application site erosion | General disorders | SAD Cohort 2 Danicamtiv 500mg | 0 | 4 | |
| other | Application site erosion | General disorders | SAD Cohort 2 Placebo | 0 | 4 | |
| other | Application site erosion | General disorders | MAD Cohort 1 Danicamtiv 75mg | 0 | 6 | |
| other | Application site erosion | General disorders | MAD Cohort 1 Placebo | 0 | 2 | |
| other | Application site erosion | General disorders | MAD Cohort 2 Danicamtiv 50mg | 1 | 9 | |
| other | Application site erosion | General disorders | MAD Cohort 2 Placebo | 0 | 3 | |
| other | Application site erosion | General disorders | MAD Cohort 3 Danicamtiv 75mg | 0 | 9 | |
| other | Application site erosion | General disorders | MAD Cohort 3 Placebo | 0 | 3 | |
| other | Application site erosion | General disorders | MAD Cohort 4 Danicamtiv 100mg | 0 | 6 | |
| other | Application site erosion | General disorders | MAD Cohort 4 Placebo | 0 | 2 | |
| other | Application site irritation | General disorders | SAD Cohort 1 Danicamtiv 175mg | 0 | 8 | |
| other | Application site irritation | General disorders | SAD Cohort 1 Danicamtiv 350mg | 0 | 8 | |
| other | Application site irritation | General disorders | SAD Cohort 1 Placebo | 0 | 8 | |
| other | Application site irritation | General disorders | SAD Cohort 1 Danicamtiv Optional Period D | 0 | 6 | |
| other | Application site irritation | General disorders | SAD Cohort 2 Danicamtiv 400mg | 0 | 4 | |
| other | Application site irritation | General disorders | SAD Cohort 2 Danicamtiv 500mg | 0 | 4 | |
| other | Application site irritation | General disorders | SAD Cohort 2 Placebo | 0 | 4 | |
| other | Application site irritation | General disorders | MAD Cohort 1 Danicamtiv 75mg | 1 | 6 | |
| other | Application site irritation | General disorders | MAD Cohort 1 Placebo | 0 | 2 | |
| other | Application site irritation | General disorders | MAD Cohort 2 Danicamtiv 50mg | 0 | 9 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03447990/events?page=11